PE20171340A1 - Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales - Google Patents

Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales

Info

Publication number: PE20171340A1
Authority: PE; Peru
Prior art keywords: treatment; gastrointestinal diseases; pharmaceutical composition; bismuth; composition
Prior art date: 2015-01-30

Application number

PE2017001147A

Other languages

English (en)

Spanish (es)

Inventor

Young Ho Jo

Jun Woo Lee

Original Assignee

Dae Woong Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-30

Filing date

2016-01-28

Publication date

2017-09-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171340(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-01-28 Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma

2017-09-13 Publication of PE20171340A1 publication Critical patent/PE20171340A1/es

Links

208000018522 Gastrointestinal disease Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title 1
239000000203 mixture Substances 0.000 abstract 2
229910052797 bismuth Inorganic materials 0.000 abstract 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 abstract 1
229960004645 bismuth subcitrate Drugs 0.000 abstract 1
ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 abstract 1
229960000620 ranitidine Drugs 0.000 abstract 1
229960004291 sucralfate Drugs 0.000 abstract 1
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PE2017001147A 2015-01-30 2016-01-28 Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales PE20171340A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20150015339		2015-01-30
KR1020150147513A KR101583452B1 (ko)	2015-01-30	2015-10-22	위장질환 치료용 의약 조성물

Publications (1)

Publication Number	Publication Date
PE20171340A1 true PE20171340A1 (es)	2017-09-13

Family

ID=55169799

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2017001147A PE20171340A1 (es)	2015-01-30	2016-01-28	Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales

Country Status (19)

Country	Link
EP (1)	EP3250199A4 (fr)
JP (1)	JP6419347B2 (fr)
KR (2)	KR101583452B1 (fr)
CN (1)	CN107205947B (fr)
AR (1)	AR105413A1 (fr)
CL (1)	CL2017001680A1 (fr)
CO (1)	CO2017006222A2 (fr)
EA (1)	EA032385B9 (fr)
EC (1)	ECSP17038599A (fr)
GE (2)	GEP20196941B (fr)
MA (1)	MA41432A (fr)
MX (1)	MX375765B (fr)
MY (1)	MY195824A (fr)
PE (1)	PE20171340A1 (fr)
PH (1)	PH12017550051A1 (fr)
SA (1)	SA517382016B1 (fr)
TW (1)	TWI635859B (fr)
UA (1)	UA116517C2 (fr)
WO (1)	WO2016122226A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101988479B1 (ko)	2017-10-11	2019-09-24	(주)휴럼	리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
KR102286499B1 (ko) *	2018-04-13	2021-08-05	주식회사 삼양홀딩스	레날리도마이드를 포함하는 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3874917T2 (de) *	1987-03-09	1993-03-04	Procter & Gamble	Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) *	1988-08-25	1991-02-05	Applied Analytical Industries, Inc.	Method for preparing high potency sucralfate
EP0403048A3 (fr) *	1989-06-14	1991-01-30	Warner-Lambert Company	Un modèle de structure de système craniomandibulaire humain
KR970006083B1 (ko) *	1992-01-22	1997-04-23	주식회사 대웅제약	위장질환 치료용 의약 조성물
CN1081921C (zh) *	1994-04-26	2002-04-03	中外制药株式会社	硫糖铝的熔融造粒制剂及其制造方法
JPH0879097A (ja) *	1994-09-01	1996-03-22	Matsushita Electric Ind Co Ltd	携帯無線機
KR970006083A (ko)	1995-07-06	1997-02-19	한승준	자동차용 카울부의 와이어 고정장치 취부구조
WO1999010000A1 (fr) *	1997-08-25	1999-03-04	The Procter & Gamble Company	Preparations combinees pour le traitement des douleurs du tractus gastro-intestinal superieur
WO2000078307A1 (fr) *	1999-06-21	2000-12-28	Daewoong Pharmaceutical Co., Ltd.	Preparation pharmaceutique a administration orale ayant une action therapeutique sur les troubles gastro-intestinaux, contenant de la ranitidine enrobee, du sous-citrate de bismuth et du sucralfate
JP2006076956A (ja) *	2004-09-10	2006-03-23	Taiyo Yakuhin Kogyo Kk	胃炎の治療・予防用配合剤
KR101617054B1 (ko) *	2008-07-01	2016-04-29	라이온 가부시키가이샤	고형내복제제
KR20110105223A (ko) *	2010-03-18	2011-09-26	일양약품주식회사	일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) *	2012-12-05	2014-06-13	(주)한국파비스제약	경구용 위장질환 치료를 위한 정제

2015
- 2015-10-22 KR KR1020150147513A patent/KR101583452B1/ko active Active
- 2015-12-31 KR KR1020150190850A patent/KR20160094268A/ko not_active Withdrawn
2016
- 2016-01-27 TW TW105102582A patent/TWI635859B/zh active
- 2016-01-27 MA MA041432A patent/MA41432A/fr unknown
- 2016-01-28 GE GEAP201614551A patent/GEP20196941B/en unknown
- 2016-01-28 EA EA201791458A patent/EA032385B9/ru not_active IP Right Cessation
- 2016-01-28 CN CN201680007680.7A patent/CN107205947B/zh active Active
- 2016-01-28 EP EP16743704.5A patent/EP3250199A4/fr not_active Withdrawn
- 2016-01-28 MX MX2017007567A patent/MX375765B/es active IP Right Grant
- 2016-01-28 PE PE2017001147A patent/PE20171340A1/es unknown
- 2016-01-28 UA UAA201707833A patent/UA116517C2/uk unknown
- 2016-01-28 JP JP2017540683A patent/JP6419347B2/ja active Active
- 2016-01-28 GE GEAP201814551A patent/GEP20186941B/en unknown
- 2016-01-28 WO PCT/KR2016/000935 patent/WO2016122226A2/fr not_active Ceased
- 2016-01-28 MY MYPI2017702737A patent/MY195824A/en unknown
- 2016-01-29 AR ARP160100272A patent/AR105413A1/es not_active Application Discontinuation
2017
- 2017-06-20 EC ECIEPI201738599A patent/ECSP17038599A/es unknown
- 2017-06-23 CO CONC2017/0006222A patent/CO2017006222A2/es unknown
- 2017-06-23 CL CL2017001680A patent/CL2017001680A1/es unknown
- 2017-07-25 PH PH12017550051A patent/PH12017550051A1/en unknown
- 2017-07-29 SA SA517382016A patent/SA517382016B1/ar unknown

Also Published As

Publication number	Publication date
MY195824A (en)	2023-02-22
EA032385B1 (ru)	2019-05-31
EP3250199A2 (fr)	2017-12-06
MX2017007567A (es)	2017-10-19
BR112017013857A2 (pt)	2018-02-27
KR101583452B9 (ko)	2022-05-02
JP6419347B2 (ja)	2018-11-07
CO2017006222A2 (es)	2017-09-20
CL2017001680A1 (es)	2018-01-12
MX375765B (es)	2025-03-07
SA517382016B1 (ar)	2021-03-18
EA201791458A1 (ru)	2017-11-30
EP3250199A4 (fr)	2018-08-08
KR20160094268A (ko)	2016-08-09
PH12017550051A1 (en)	2018-01-29
JP2018503672A (ja)	2018-02-08
TWI635859B (zh)	2018-09-21
GEP20186941B (en)	2019-01-10
GEAP201814551A (en)	2018-08-27
KR101583452B1 (ko)	2016-01-11
MA41432A (fr)	2017-12-05
CN107205947B (zh)	2020-05-22
TW201639559A (zh)	2016-11-16
WO2016122226A2 (fr)	2016-08-04
UA116517C2 (uk)	2018-03-26
AR105413A1 (es)	2017-10-04
ECSP17038599A (es)	2017-09-29
EA032385B9 (ru)	2019-07-31
WO2016122226A3 (fr)	2016-09-15
CN107205947A (zh)	2017-09-26
GEP20196941B (en)	2019-01-10

Publication	Publication Date	Title
CL2018003681A1 (es)	2019-04-26	Derivados de ácido borónico y usos terapéuticos de los mismos
AR104984A1 (es)	2017-08-30	Compuestos selectivos para pyy y sus usos
GT201500053A (es)	2015-10-12	Composicion farmaceutica recubierta que contiene regorafenib
EA201691988A1 (ru)	2017-06-30	Производные бороновой кислоты и их терапевтическое применение
CL2016001918A1 (es)	2017-01-13	Heteroaril amidas como inhibidores de agregación de proteína
MX2015012559A (es)	2016-07-18	Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
PE20211069A1 (es)	2021-06-09	Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
MX2018002462A (es)	2018-06-19	Una composicion farmaceutica para reducir la grasa localizada y sus usos.
MX389178B (es)	2025-03-20	Formulacion de proporcion fija de insulina glargina/lixisenatida.
ECSP16084317A (es)	2018-05-31	Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EA201691490A1 (ru)	2016-12-30	Фармацевтическая композиция, содержащая бринзоламид
BR112016027435A2 (pt)	2017-10-17	formulação inovadora de meloxicam
EA201590797A1 (ru)	2016-02-29	Препараты с модифицированным высвобождением опрозомиба
CR20160529A (es)	2017-01-02	Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2017013636A (es)	2018-03-08	Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
GT201700016A (es)	2018-12-19	[1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
BR112014032583A2 (pt)	2017-06-27	forma farmacêutica para liberação prolongada de substâncias ativas
CL2019003288A1 (es)	2020-05-08	Una combinación farmacéutica para el tratamiento de un cáncer.
PE20171340A1 (es)	2017-09-13	Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales
CL2018002848A1 (es)	2018-12-21	Formulaciones liquidas de fosfoplatino
MX2019009909A (es)	2019-10-14	Composiciones farmaceuticas para terapia de combinacion.
CL2017000026A1 (es)	2017-07-28	Formas de dosificación farmacéutica
CO2018010142A2 (es)	2018-10-22	Proceso de preparación de fórmulas solidas de mesalazina
JOP20200005B1 (ar)	2024-04-18	تركيبات صيدلية
EA202091403A1 (ru)	2020-10-14	Производные 2-оксо-1-пирролидинилимидазотиадиазола